Companies Dominating the Germ Cell Tumor Market
- Eli Lilly and Company
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- BioNTech SE
- ImmunoGen Inc.
- Teva Pharmaceutical Industries Ltd.
- Accord Healthcare Limited
- Sandoz International GmbH
- Lundbeck A/S
- Pfizer Inc.
- Merck & Co.
- Kyowa Hakko Kirin Co., Ltd.
- Baxter International Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of germ cell tumor is evaluated at USD 14.29 billion.
The germ cell tumor market size was valued at USD 13.87 billion in 2024 and is set to exceed USD 22.52 billion by 2037, registering over 3.8% CAGR during the forecast period i.e., between 2025-2037. The growing prevalence of germ cell tumor, the growing geriatric population will drive the market growth.
North America industry is anticipated to dominate majority revenue share of 35% by 2037, backed by expansion in R&D in the region.
The major players in the market include Eli Lilly and Company, BioNTech SE, ImmunoGen Inc., Teva Pharmaceutical Industries Ltd., Accord Healthcare Limited, Sandoz International GmbH, Lundbeck A/S, Pfizer Inc., Merck & Co., Kyowa Hakko Kirin Co., Ltd., Baxter International Inc.
